Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral parkinson disease

Neurochemical Research

Volumn 35, Issue 4, 2010, Pages 613-619

  Lee, Ho Joo ^a   Bazinet, Richard P ^a   Rapoport, Stanley I ^a   Bhattacharjee, Abesh Kumar ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

6 OHDA; Arachidonic acid; Asymmetry; Cascade; Cyclooxygenase 2; Cytosolic phospholipase A 2; Dopamine; Parkinson disease; Rat; Signaling; Unilateral; Upregulation

Indexed keywords

ARACHIDONIC ACID; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVITY; FRONTAL CORTEX; MALE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ARACHIDONIC ACID; BLOTTING, WESTERN; BRAIN; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; MALE; OXIDOPAMINE; PARKINSON DISEASE; PHOSPHOLIPASES A2; RATS; RATS, INBRED F344; UP-REGULATION;

RATTUS;

EID: 77953534900     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-009-0106-6     Document Type: Article

References (72)

1. Hornykiewicz O (1982) Imbalance of brain monoamines and clinical disorders. Prog Brain Res 55:419-429
2. Heiss WD, Hilker R (2004) The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 11:5-12
3. Lang AE, Lozano AM (1998) Parkinson's disease. Second of two parts. N Engl J Med 339:1130-1143
4. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041
5. UngerstedtU(1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-93
6. Yuan H, Sarre S, Ebinger G, Michotte Y (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 144:35-45
7. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317
8. Jeon BS, Jackson-Lewis V, Burke RE (1995) 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 4:131-137
9. Arnt J, Hyttel J (1985) Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) 85:346-352
10. Cadet JL, Zhu SM (1992) The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res 595:316-326
11. Zuch CL, Nordstroem VK, Briedrick LA, Hoernig GR, Granholm AC, Bickford PC (2000) Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 427:440-454
12. Nikolaus S, Larisch R, Beu M, Forutan F, Vosberg H, Muller-Gartner HW (2003) Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging 30:390-395
13. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr et al (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432
14. Graham WC, Crossman AR, Woodruff GN (1990) Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res 514:93-102
15. Chalon S, Emond P, Bodard S, Vilar MP, Thiercelin C, Besnard JC et al (1999) Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse 31:134-139
16. 2+-dependent translocation domain with homology to PKC and GAP. Cell 65:1043-1051
17. Axelrod J (1990) Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction. Biochem Soc Trans 18:503-507
18. Nilsson CL, Hellstrand M, Ekman A, Eriksson E (1998) Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. Br J Pharmacol 124:1651-1658
19. Vial D, Piomelli D (1995) Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonatespecific phospholipase A2. J Neurochem 64:2765-2772
20. Ong WY, Sandhya TL, Horrocks LA, Farooqui AA (1999) Distribution of cytoplasmic phospholipase A2 in the normal rat brain. J Hirnforsch 39:391-400
21. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93:2317-2321
22. Hayakawa T, Chang MC, Bell JM, Seeman R, Rapoport SI, Appel NM (1998) Fatty acid incorporation depicts brain activity in a rat model of Parkinson's disease. Brain Res 807:177-181
23. Bhattacharjee AK, Meister LM, Chang L, Bazinet RP, White L, Rapoport SI (2007) In vivo imaging of disturbed pre-and postsynaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease. Neuroimage 37:1112-1121
24. Hayakawa T, Chang MC, Rapoport SI, Appel NM (2001) Selective dopamine receptor stimulation differentially affects [3H]arachidonic acid incorporation, a surrogate marker for phospholipase A2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease. J Pharmacol Exp Ther 296:1074-1084
25. Shimizu T, Wolfe LS (1990) Arachidonic acid cascade and signal transduction. J Neurochem 55:1-15
26. Fitzpatrick FA, Soberman R (2001) Regulated formation of eicosanoids. J Clin Invest 107:1347-1351
27. Basselin M, Chang L, Bell JM, Rapoport SI (2005) Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology 30:1064-1075 (Pubitemid 40720964)
28. Rapoport SI (2008) Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot Essent Fatty Acids 79:153-156
29. Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269:13057-13060
30. Basselin M, Villacreses NE, Langenbach R, Ma K, Bell JM, Rapoport SI (2006) Resting and arecoline-stimulated brain metabolism and signaling involving arachidonic acid are altered in the cyclooxygenase-2 knockout mouse. J Neurochem 96:669-679
31. Takano T, Panesar M, Papillon J, Cybulsky AV (2000) Cyclooxygenases-1 and 2 couple to cytosolic but not group IIA phospholipase A2 in COS-1 cells. Prostaglandins Other Lipid Mediat 60:15-26
32. Strokin M, Sergeeva M, Reiser G (2007) Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2. J Neurochem 102:1771-1782
33. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493
34. Inaji M, Okauchi T, Ando K, Maeda J, Nagai Y, Yoshizaki T et al (2005) Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 1064:136-145
35. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415
36. Lucas KK, Dennis EA (2005) Distinguishing phospholipase A2 types in biological samples by employing group-specific assays in the presence of inhibitors. Prostaglandins Other Lipid Mediat 77:235-248
37. Yang HC, Mosior M, Johnson CA, Chen Y, Dennis EA (1999) Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal Biochem 269:278-288
38. Bhattacharjee AK, Chang L, Lee HJ, Bazinet RP, Seemann R, Rapoport SI (2005) D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology (Berl) 180:735-742
39. Bhattacharjee AK, Chang L, White L, Bazinet RP, Rapoport SI (2006) D-Amphetamine stimulates D2 dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats. J Cereb Blood Flow Metab 26:1378-1388 (Pubitemid 44629886)
40. Kanterman RY, Axelrod J, Felder CC (1990) Alpha-1 adrenergic receptor mediates the release of arachidonic acid in spinal cord neurons independent of phosphatidylinositol-specific phospholipase C. Adv Second Messenger Phosphoprotein Res 24:158-163
41. Schinelli S, Paolillo M, Corona GL (1994) Opposing actions of D1-and D2-dopamine receptors on arachidonic acid release and cyclic AMP production in striatal neurons. J Neurochem 62: 944-949
42. Wei S, Ong WY, Thwin MM, Fong CW, Farooqui AA, Gopalakrishnakone P et al (2003) Group IIA secretory phospholipase A2 stimulates exocytosis and neurotransmitter release in pheochromocytoma-12 cells and cultured rat hippocampal neurons. Neuroscience 121:891-898
43. Ribeiro MJ, Vidailhet M, Loćh C, Dupel C, Nguyen JP, Ponchant M et al (2002) Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 59:580-586
44. Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F et al (1999) SPECT imaging of pre-and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 52:1206-1214
45. Ross BM, Mamalias N, Moszczynska A, Rajput AH, Kish SJ (2001) Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease. Neuroscience 102:899-904
46. Giovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC et al (2004) Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med 45:1471-1479
47. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378:180-182
48. Esposito G, Giovacchini G, Der M, Liow JS, Bhattacharjee AK, Ma K et al (2007) Imaging signal transduction via arachidonic acid in the human brain during visual stimulation, by means of positron emission tomography. Neuroimage 34:1342-1351
49. Esposito G, Giovacchini G, Liow JS, Bhattacharjee AK, Greenstein D, Schapiro M et al (2008) Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J Nucl Med 49:1414-1421
50. Tay A, Simon JS, Squire J, Hamel K, Jacob HJ, Skorecki K (1995) Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 26:138-141
51. Pardue S, Rapoport SI, Bosetti F (2003) Co-localization of cytosolic phospholipase A2 and cyclooxygenase-2 in Rhesus monkey cerebellum. Brain Res Mol Brain Res 116:106-114
52. Balsinde J, Balboa MA, Dennis EA (1998) Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc Natl Acad Sci USA 95:7951-7956
53. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991-998
54. Rosenberger TA, Villacreses NE, Hovda JT, Bosetti F, Weerasinghe G, Wine RN et al (2004) Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. J Neurochem 88:1168-1178
55. Richardson RL, Kim EM, Gardiner T, O'Hare E (2005) Chronic intracerebroventricular infusion of lipopolysaccharide: effects of ibuprofen treatment and behavioural and histopathological correlates. Behavioural pharmacology 16:531-541
56. Lee H, Villacreses NE, Rapoport SI, Rosenberger TA (2004) In vivo imaging detects a transient increase in brain arachidonic acid metabolism: a potential marker of neuroinflammation. J Neurochem 91:936-945
57. Anthonsen MW, Solhaug A, Johansen B (2001) Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-alpha-and interleukin-1betainduced NF-kappa B activation. J Biol Chem 276:30527-30536
58. Mirza B, Hadberg H, Thomsen P, Moos T (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95:425-432
59. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23:474-483
60. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382-397
61. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202:17-20
62. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ et al (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58:963-967
63. Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836-1842
64. Bornebroek M, De Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH et al (2007) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28:193-196
65. Samii A, Etminan M, Wiens MO, Jafari S (2009) NSAID use and the risk of Parkinson's disease: systematic review and metaanalysis of observational studies. Drugs Aging 26:769-779
66. Xiao L, Patterson PS, Yang C, Lal AA (1999) Role of eicosanoids in the pathogenesis of murine cerebral malaria. Am J Trop Med Hyg 60:668-673
67. McGahon B, Clements MP, Lynch MA (1997) The ability of aged rats to sustain long-term potentiation is restored when the age-related decrease in membrane arachidonic acid concentration is reversed. Neuroscience 81:9-16
68. Sellmayer A, Danesch U, Weber PC (1997) Modulation of the expression of early genes by polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 57:353-357
69. Bazan NG (2005) Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 32:89-103
70. Ikemoto A, Kobayashi T, Emoto K, Umeda M, Watanabe S, Okuyama H (1999) Effects of docosahexaenoic and arachidonic acids on the synthesis and distribution of aminophospholipids during neuronal differentiation of PC12 cells. Arch Biochem Biophys 364:67-74
71. Stefanovic B, Bosetti F, Silva AC (2006) Modulatory role of cyclooxygenase-2 in cerebrovascular coupling. Neuroimage 32:23-32
72. Adibhatla RM, Hatcher JF (2008) Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep 41:560-567